The Growing Armamentarium Against EGFR Exon 20+ Non–Small Cell Lung Cancer
Joshua K. Sabari, MD, reviews the therapies available to treat patients with EGFR exon 20-positive non–small cell lung cancer.
Joshua K. Sabari, MD, assistant professor, Department of Medicine, NYU Grossman School of Medicine, reviews the therapies available to treat patients with EGFR exon 20-positive non–small cell lung cancer (NSCLC).
In recent years, there was an explosion of therapeutic opportunities for patients with EGFR exon 20 insertion mutant NSCLC, Sabari says. The two avenues of therapies are EGFR exon 20-directed tyrosine kinase inhibitors such as mobocertinib, which is a small molecule that specifically inhibits EGFR exon 20. Sabari explains that there are many other exon 20-specific TKIs in development, such as BDTX-189 and CLN-081. Older agents like poziotinib are also still effective for the treatment of this patient population.
Most recently, the FDA granted approval to amivantamab-vmjw (Rybrevant), an agent that has been shown to have activity in exon 20 insertion mutant disease.
Zipalertinib Shows Promise in Heavily Pretreated EGFR Exon 20-Mutated NSCLC
September 14th 2024Zipalertinib appeared safe and effective in the treatment of heavily pretreated patients with non-small cell lung cancer harboring EGFR exon 20 insertion mutations who progressed on or after amivantamab.
Read More
Amivantamab/Lazertinib Shows Potential in Atypical EGFR-Mutant Lung Cancer
August 20th 2024Byoung Chul Cho, MD, PhD, discussed findings from cohort C of the CHYRSALIS-2 study exploring amivantamab plus lazertinib in patients with non–small cell lung cancer with uncommon EGFR mutations.
Read More
FDA Clears Lazertinib/Amivantamab for First-Line EGFR-Mutated NSCLC
August 20th 2024Lazertinib and amivantamab as a first-line treatment for patients with locally advanced or metastatic non–small cell lung cancer with specific EGFR mutations demonstrated superior efficacy compared with standard treatment.
Read More
